Free tool
FAERS Monitor: Klaron
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019931 or its brand name (Klaron, Sulfacetamide Sodium). Reports on generic versions are filed under their own applications.
Reports
580
Serious
250
43% of reports
Hospitalization
91
Death reported
15
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity66
- drug ineffective55
- nausea36
- off label use35
- headache31
- pain30
- dyspnoea29
- rash28
- fatigue25
- weight decreased24
- vomiting20
- diarrhoea19
- erythema19
- pruritus19
- asthenia18
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 10 |
| 2006 | 3 |
| 2007 | 8 |
| 2008 | 5 |
| 2009 | 12 |
| 2010 | 20 |
| 2011 | 14 |
| 2012 | 18 |
| 2013 | 25 |
| 2014 | 13 |
| 2015 | 25 |
| 2016 | 49 |
| 2017 | 38 |
| 2018 | 42 |
| 2019 | 54 |
| 2020 | 31 |
| 2021 | 25 |
| 2022 | 49 |
| 2023 | 35 |
| 2024 | 32 |
| 2025 | 35 |
| 2026 | 35 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,579 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 66 | 12.4 | 9.9 | 685 |
| erythemaSignal | 19 | 3.4 | 2.2 | 29 |
| weight decreasedSignal | 24 | 3.1 | 2.1 | 33 |
| rashSignal | 28 | 2.3 | 1.6 | 20 |
| dyspnoea | 29 | 1.9 | 1.3 | 11 |
| headache | 31 | 1.8 | 1.3 | 10 |
| pruritus | 19 | 1.8 | 1.2 | 6 |
| pain | 30 | 1.8 | 1.2 | 10 |
| asthenia | 18 | 1.7 | 1.1 | 5 |
| nausea | 36 | 1.6 | 1.2 | 9 |
| vomiting | 20 | 1.5 | 1.0 | 3 |
| drug ineffective | 55 | 1.5 | 1.2 | 10 |
| off label use | 35 | 1.4 | 1.1 | 5 |
| fatigue | 25 | 1.2 | 0.8 | 0 |
| diarrhoea | 19 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.